133P - An estimation of the population-based survival benefit of first-line chemotherapy for lung cancer

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Viet Do
Citation Annals of Oncology (2015) 26 (suppl_1): 29-44. 10.1093/annonc/mdv050
Authors V. Do, W. Ng, S. Jacob, G. Delaney, M. Barton
  • Collaboration For Cancer Outcomes Research And Evaluation (ccore), Ingham Institute for Applied Medical Research, University of New South Wales, 2170 - Liverpool/AU

Abstract

Aim/Background

Randomized clinical trials and meta-analyses describe the benefit of chemotherapy and combined chemoradiotherapy for specific subgroups of lung (small cell lung cancer SCLC and non-small cell lung cancer NSCLC) cancer patients with selected patient and disease characteristics but not an entire lung cancer population. This study estimates the overall survival (OS) benefit for the whole population of lung cancer patients in Australia if evidence-based guidelines for chemotherapy were followed.

Methods

An evidence-based optimal chemotherapy utilization rate for lung cancer (the proportion of new patients in whom chemotherapy is indicated at least once) has been previously defined [1].The benefits of chemotherapy were extracted from published trials. Multiple electronic citation databases were systematically queried, including Medline and the Cochrane Library. The benefits of chemotherapy were estimated for 1- and 5-year survival. Sensitivity analyses were performed to assess the robustness of our estimates.

Results

First-line chemotherapy was indicated in 73.2% of patients with lung cancer. The estimated 1 and 5-year absolute OS benefits of first-line chemotherapy for the whole population of patients with lung cancer in Australia were 9.4% and 2.9%, respectively. They are summarized as below.

Lung Cancer Estimation of Population-based 1-yr OS benefit Estimation of Population-based 5-yr OS benefit Total proportion of lung cancer population
SCLC 17.6% 3.0% 18.0%
NSCLC 7.6% 2.9% 82.0%
Lung Cancer 9.4% 2.9% 100.0%

Conclusions

Chemotherapy would provide a survival benefit of 9.4% at 1 year when applied to the entire lung cancer patient population in Australia if all patients with an indication for chemotherapy were treated.

Disclosure

All authors have declared no conflicts of interest.